| abstract |
2- (3- (6- (2- (2,4-Dichloro-phenyl) -ethylamino) -2-methoxy-pyrimidin-4-yl) -phenyl) -2-methyl-propionic acid dihydrogen phosphate salt Formula (III), a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of Formula (III), and a pharmaceutically acceptable carrier; and a method of treating a patient suffering from a disorder mediated by PGD2. Compositions of this compound are also claimed with an antihistamine, a leukotriene antagonist, a beta antagonist, a PDEA4 inhibitor, a TP antagonist, and a CrTh2 antagonist. |